Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis

May 27, 2014

NESS ZIONA, Israel, May 27, 2014 /PRNewswire/ –

Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and
high value-added generic drugs, announced today that its US patent for the company’s
Glatiramer Acetate Depot has been extended until December 2030.

The notice of allowance for US Patent Application No. 13/258,808 entitled Depot
Systems Comprising Glatiramer or Pharmacologically Acceptable Salt Thereof, also awarded
additional claims to an earlier patent (U.S. Patent 8,377,885), issued to the company in
February 2013.

The additional claims include:

        - administration from about two weeks to about once-a-month for glatiramer
          salts, including glatiramer acetate;
        - administration from about once-a-week to about six months for salts other than
          glatiramer acetate; and,
        - glatiramer salts Depot, including glatiramer acetate, in combination with at
          least one additional drug.

The Glatiramer Acetate Depot formulation is a Life Cycle Management product of
Copaxone(R) to be injected between once-a-week and up to once-every-six-months
subcutaneously (under the skin) or intramuscularly (into the muscle) for prolonged release
of the therapeutic agent, thereby allowing for increased compliance and a reduced burden
of treatment.

MS is a chronic, often disabling disease that attacks the central nervous system.
Symptoms include numbness in the limbs, paralysis and loss of vision. Symptoms are
unpredictable and differ from one person to another. According to Thomson Reuters
Cortellis’ website, the global market for MS pharmaceuticals is estimated to be
approximately US $15 billion.

About Mapi-Pharma

Mapi Pharma Ltd. (“Mapi” or the “Company”) is a developer of high-barrier to entry and
high value-added generic drugs that include complex active pharmaceutical ingredients
(“APIs”), formulations and life cycle management (“LCM”) products that target large
markets. Mapi is dedicated to providing generic and innovative intermediates and APIs, as
well as developing finished dosage forms, either for Mapi’s internal API program, as a
vertically integrated company, or as generics of leading brands. Mapi is headquartered in
Israel. It has R&D facilities in Israel, China and Germany and is currently building an
API manufacturing site in Neot Hovav, Israel’s designated chemical park. Mapi has filed
more than 20 patent applications for APIs and formulations in less than four years of
operation. For more information: http://www.mapi-pharma.com.

Forward Looking Statements

This press release contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown risks and uncertainties,
many of which are beyond the Company’s control, and cannot be predicted or quantified and
consequently, actual results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, without limitation,
risks and uncertainties associated with (i) the adequacy of the Company’s financial and
other resources, particularly in light of its history of recurring losses and the
uncertainty regarding the adequacy of its liquidity to pursue its complete business
objectives; (ii) the Company’s ability to commercialize its pharmaceutical products; (iii)
the Company’s ability to obtain and maintain adequate protection of its intellectual
property; (iv) the Company’s ability to complete the development of its products; (v) the
Company’s ability to find suitable co-development partners; (vi) the Company’s ability to
manufacture its products in commercial quantities, at an adequate quality or at an
acceptable cost; (vii) the Company’s ability to establish adequate sales, marketing and
distribution channels; (viii) acceptance of the Company’s products by healthcare
professionals and patients; (ix) the possibility that the Company may face third party
claims of intellectual property infringement; (x) the Company’s ability to obtain or
maintain regulatory approvals for its products in its target markets and the possibility
of adverse regulatory or legal actions relating to its products even if regulatory
approval is obtained; (xi) the results of clinical trials that the Company may conduct or
that its competitors and others may conduct relating to its or their products; (xii)
intense competition in the Company’s industry, with competitors having substantially
greater financial, technological, research and development, regulatory and clinical,
manufacturing, marketing and sales, distribution and personnel resources than the Company;
(xiii) potential product liability claims; (xiv) potential adverse federal, state and
local government regulation, in the United States, Europe or Israel and (xv) loss or
retirement of key executives and research scientists. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.

        Press Contact
        Marjie Hadad
        Media Liaison
        Mapi Pharma

SOURCE Mapi Pharma Ltd

Source: PR Newswire

comments powered by Disqus